Athersys, Inc. (NASDAQ:ATHX) shares traded up 7.2% during trading on Monday . The stock traded as high as $1.84 and last traded at $1.79. 1,534,248 shares traded hands during trading, an increase of 51% from the average session volume of 1,017,098 shares. The stock had previously closed at $1.67.

Several research analysts recently commented on the stock. ValuEngine cut shares of Athersys from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Zacks Investment Research cut shares of Athersys from a “buy” rating to a “hold” rating in a report on Tuesday, August 22nd. Finally, Maxim Group restated a “buy” rating and set a $12.00 target price on shares of Athersys in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $7.17.

In other Athersys news, COO William Lehmann, Jr. sold 14,000 shares of the stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $1.80, for a total value of $25,200.00. Following the completion of the sale, the chief operating officer now owns 503,712 shares in the company, valued at $906,681.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 29,000 shares of company stock valued at $51,075. Corporate insiders own 9.40% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Athersys by 19.5% in the first quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock valued at $6,668,000 after acquiring an additional 637,322 shares during the last quarter. Royal Bank of Canada lifted its stake in Athersys by 7,334.0% in the second quarter. Royal Bank of Canada now owns 380,846 shares of the biopharmaceutical company’s stock valued at $576,000 after acquiring an additional 375,723 shares during the last quarter. Perkins Capital Management Inc. acquired a new stake in Athersys in the third quarter valued at $636,000. Geode Capital Management LLC raised its position in shares of Athersys by 35.2% in the first quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock valued at $1,292,000 after purchasing an additional 196,981 shares during the period. Finally, Northern Trust Corp raised its position in shares of Athersys by 30.8% in the second quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock valued at $1,697,000 after purchasing an additional 264,549 shares during the period. Hedge funds and other institutional investors own 21.01% of the company’s stock.

WARNING: “Athersys (ATHX) Trading Up 7.2%” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/athersys-athx-trading-up-7-2/1774429.html.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.